KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBT (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of EBT data on record, last reported at $55.2 million in Q4 2025.

  • For Q4 2025, EBT rose 460.57% year-over-year to $55.2 million; the TTM value through Dec 2025 reached $139.2 million, up 353.05%, while the annual FY2025 figure was $139.2 million, 353.05% up from the prior year.
  • EBT reached $55.2 million in Q4 2025 per AMRX's latest filing, up from -$5.2 million in the prior quarter.
  • Across five years, EBT topped out at $55.2 million in Q4 2025 and bottomed at -$232.7 million in Q2 2022.
  • Average EBT over 5 years is -$8.6 million, with a median of $68500.0 recorded in 2021.
  • The widest YoY moves for EBT: up 953.07% in 2023, down 990.28% in 2023.
  • A 5-year view of EBT shows it stood at -$16.3 million in 2021, then surged by 53.09% to -$7.7 million in 2022, then crashed by 990.28% to -$83.5 million in 2023, then skyrocketed by 81.65% to -$15.3 million in 2024, then skyrocketed by 460.57% to $55.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $55.2 million in Q4 2025, -$5.2 million in Q3 2025, and $51.7 million in Q2 2025.